benefits of combining cd38 inhibitor with 5-amino-1mq Nicotinamide N-Methyltransferase (NNMT) and Liver Cancer: From Metabolic Networks to Therapeutic Targets Anti-CD38 antibody therapy for patients
Description
52,53 The increasing range of mechanisms available in the relapsed/refractory setting of multiple myeloma has greatly broadened the available regimens for the later-line management of disease
WITHDRAWAL TIMES: 0 DAY
It is characterized by frameshifting or nonsense mutations in the dystrophin protein gene, which is essential for maintaining the membrane integrity of muscle fibers 265
The Future of Multiple Myeloma Treatment: Expert Q&A on Bispecific Antibodies
